The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
暂无分享,去创建一个
Hidekazu Suzuki | F. Imamura | T. Hirashima | M. Tamiya | A. Tamiya | S. Atagi | T. Kumagai | N. Okamoto | K. Nishino | Y. Taniguchi